Introduction {#S1}
============

*Staphylococcus aureus* is the etiologic agent of a wide spectrum of clinical conditions ranging from superficial skin infections and soft tissue infections to severe sepsis ([@B4]; [@B39]; [@B62]). The indiscriminate use of antibiotic has induced the emergence of multidrug resistant (MDR) strains that have spread from hospital settings to different environmental and victimized various individuals ([@B39]; [@B62]).

Indeed, both hospital- and community-associated *S. aureus* strains display complex combinations of virulence and resistance genes and have been related to increased ratios of morbidly and mortality and represent serious concerns for global systems worldwide ([@B11]; [@B35]; [@B63]). The major drugs currently used against methicillin-resistant *S. aureus* (MRSA) are vancomycin, teicoplanin, linezolid, and daptomycin ([@B65]); however, isolates with resistance or low susceptibility have been detected for all these drugs ([@B14]; [@B30]; [@B7]; [@B5]). Taken together, these data justify the search for new alternatives for the treatment of infections caused by *S. aureus*, and plant-derived products are highlighted as interesting candidates ([@B12]; [@B42]).

Plants are known to produce a large variety of molecules with interest for pharmaceutic and food industries, among them are the volatile compounds present in the essential oils (EOs) ([@B1]; [@B42]; [@B56]; [@B59]; [@B48]). EOs are complex mixture of secondary metabolites produced by aromatic plants usually involved in their protection against pathogens ([@B42]). Several EOs have been demonstrated as efficient antimicrobial agents able to inhibit different MDR strains and to improve the activity of antibiotics ([@B32]; [@B42]; [@B48]). The EOs components can interact with multiple targets in bacteria such as membrane, proteins synthesis, as well as inhibit efflux pumps and virulence related pathways (such as biofilm formation and toxin production) ([@B12]; [@B26]; [@B28]; [@B24]; [@B42]; [@B49]; [@B15]).

*Eugenia brejoensis* is an EO-bearing plant from *Mytaceae* family which has been described as an endemic species in Brazil (present in the states of Pernambuco, Sergipe, Alagoas, Paraíba, Espirito Santo) ([@B38]; [@B17]; [@B40]). The *E. brejoensis* EO (EbEO) is mainly composed by sesquiterpenes (such as δ-cadinene, β-caryophyllene, and α-muurolol) ([@B9]). EbEO has shown inhibitory actions against *Aedes aegypti* larvae ([@B9]) and *Trypanosoma cruzi* ([@B46]). In relation to antibacterial activity, nanoemulsions of EbEO were able to inhibit the growth of *Pseudomonas fluorescens* ([@B40]). The present work aims to demonstrate the efficacy of EbEO against *S. aureus* using *in vitro* and *in vivo* invertebrate models (*Caenorhabditis elegans* and *Galleria mellonella*).

Materials and Methods {#S2}
=====================

Plant Material {#S2.SS1}
--------------

Leaves of *E. brejoensis* were collected at *Parque Nacional do Catimbau* (Pernambuco, Brazil) on dry season (September, 2015). All the plant material was processed following the usual techniques in taxonomy and deposited in the Herbarium of *Instituto Agronomico de Pernambuco* (voucher access number: IPA 84.033). The EO was obtained from leaves of *E. brejoensis* (EbEO) by hydrodistillation as previously reported ([@B9]). The oil used in this study was characterized by gas chromatography--mass spectrometry (GC/MS) and the chemical profile was published by [@B9].

Bacterial Strains Used in the Study {#S2.SS2}
-----------------------------------

The standard strain *S. aureus* ATCC 29312 was used in most of the assays. The antimicrobial activity of EbEO was further analyzed against a collection of clinical isolates of *S. aureus* deposited in the Microbial Collection of *Departamento de Antibioticos* from *Universidade Federal de Pernambuco* (UFPEDA). The antibiotic resistance profile of each strain is shown in [Table 1](#T1){ref-type="table"}. The strains used in the present study are part of Dr. Anders Løbner-Olesen collection at University of Copenhagen. The expression of virulence- and SOS-related genes (*hla*, *spa*, or *recA*) was performed using strains carrying the targeted genes fused with *lacZ* (which encodes for β-galactosidase) ([@B44]; [@B18]). The strains in [Table 1](#T1){ref-type="table"} were kindly shared by Prof. Hanne Ingmer, Copenhagen University.

###### 

Antimicrobial effects of EbEO in association to antibiotics.

  ***S. aureus***           **Source**                 **Resistance profile**                                            **MIC (μg/mL)**
  ------------------------- -------------------------- ----------------------------------------------------------------- -----------------
  ATCC 29213                Standard strain            --                                                                128
  UFPEDA 02 (= ATCC 6538)   Standard strain            --                                                                256
  UFPEDA 659                Catheter tip               NAL/OXA                                                           128
  UFPEDA 671                Bone fragment              AMI/AMP/CIP/CLI/CLO/GEN/NAL/OXA/TET/TRI                           512
  UFPEDA 679                Surgical wound secretion   AMI/CLI/AMP/CFL/CFZ/NAL/OXA/VAN                                   128
  UFPEDA 683                Purulent exudate           AMI/AMP/CIP/CFL/CFO/CFZ/CLI/CLO/CPM/CRX/CTX/GEN/NAL/OXA/TRI/VAN   8
  UFPEDA 691                Catheter tip               CIP/CLO/NAL                                                       128
  UFPEDA 705                Surgical wound             AMP/CFL/CFO/CPM/CRX/NAL/NIT/OXA/GEN                               256
  UFPEDA 726                Nasal secretion            AMP/CIP/CLO/GEN/OXA/TRI                                           128
  UFPEDA 731                Surgical wound secretion   AMP/CFL/CFO/CLI/CLO/CRX/CIP/GEN/NAL/OXA/TRI                       512
  UFPEDA 802                Nasal secretion            AMI/AMP/OXA/CFL/CFO/CFZ/CIP/CLI/CLO/CPM/CRX/CTX/GEN/NAL/TET/TRI   512

AMI: amikacin; AMP: ampicillin; CFL: cephalothin; CFZ: cefazolin; CPM: cefepime; CFO: cefoxitin; CIP: ciprofloxacin; CLI: clindamycin; CLO: chloramphenicol; CRX: cefuroxime; CTX: cefotaxime; GEN: gentamicina; IMI: imipenem; MER: meropenem; NAL: nalidixic acid; NIT: nitrofurantoin; OXA: oxacillin; TET: tetracycline; TRI: trimethoprim; VAN: vancomycin. MICs were obtained using the microdilution method as described.

Determination of Minimum Inhibitory Concentration {#S2.SS3}
-------------------------------------------------

The antimicrobial activity of EbEO was determined against the standard strains *S. aureus* ATCC 29312 and clinical isolates ([Table 1](#T1){ref-type="table"}). Serial dilutions (1024 to 2 μg/mL) of EbEO were prepared in 96-wells plates containing Luria--Bertani (LB) broth. Each well received 10 μL of a microbial suspension \[bacterial load of approximately 1.0 × 10^7^ colony forming units per milliliter (CFU/mL) for each well\]. The plates were incubated at 37°C, and after 24 h each well received 30 μL of 0.03% resazurin sodium solution (Sigma--Aldrich^®^). Following, the plates were incubated for 40 min and the minimum inhibitory concentration (MIC) was defined as the lowest concentration capable of inhibiting bacterial growth (as evaluated color change).

Time-Kill Studies {#S2.SS4}
-----------------

Overnight cultures of *S. aureus* ATCC 29312 were diluted 1:100 in LB broth and placed in a shaking water bath at 37°C until an optical density at 600 nm (OD~600~) of 0.1 was reached. This microbial suspension was distributed in fresh LB broth containing EbEO (128 or 1024 μg/mL; corresponding to 2 × MIC or 8 × MIC, higher concentrations was applied to verify action of concentrations greater than MIC50). Bacteria treated with ciprofloxacin (2 μg/mL; 2 × MIC) or without treatment were used as positive and negative controls, respectively. Cell growth was monitored in specific time points (0, 1, 2, 3, 4, and 5 h) by plating 4 μL of 10-fold-diluted suspensions from each tube in quadruplicate. The plates were incubated at 37°C for 24 h. After this period, the colonies were counted for the calculation of CFU/mL.

Combinatory Effects {#S2.SS5}
-------------------

The interaction between EbEO and some important clinical used drugs (ampicillin---25 μg/mL, ciprofloxacin---0.78 μg/mL, chloramphenicol---12.5 μg/mL, erythromycin---0.39 μg/mL, and kanamycin---6.25 μg/mL) were evaluated using checkerboard assay against *S. aureus* ATCC 29312. Fractional inhibitory concentration index (FICI) was assessed algebraically using the following equation:
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Where "EbEO" is the concentration (μg/mL) of EbEO in a given well, and MIC~EbEO~ represents the control MIC of EbEO alone. "D" is the concentration of the tested drug in a given well, and MIC~D~ represents the MIC of the tested drug alone. The interactions were defined as: (i) synergistic if FICI ≤ 0.5; (ii) additive if 0.5 \< FICI ≤ 1; (iii) non-interaction if 1 \< FICI \< 4; and (iv) antagonistic if FICI ≥ 4 ([@B10]).

Expression of Virulence- and SOS-Related Genes Through β-Galactosidase Activity {#S2.SS6}
-------------------------------------------------------------------------------

The effects of EbEO on the expression of genes related to virulence and SOS pathways were performed using *S. aureus* 8325-4 derivative strains carrying the targeted genes (*hla*, *spa*, or *recA*) fused with *lacZ* (which encodes for β-galactosidase) ([@B64]). In all assays, each strain was exponentially grown in LB medium until an OD~600~ between 0.1 and 0.2. Cells were treated with EbEO (64 μg/mL, 0.5 × MIC), and permeabilizated by toluene (1 mL) after 3 h. The β-galactosidase activity was measured using ONPG (*ortho*-nitrophenyl-β-galactoside; Sigma--Aldrich). In the assays for *recA* expression, ciprofloxacin (0.5 μg/mL) was used as positive control.

Evaluation of Staphyloxanthin (STX) Inhibition {#S2.SS7}
----------------------------------------------

Overnight cultures of *S. aureus* ATCC 29312 were diluted (1:100) in LB medium and samples (1 mL) of this suspension were incubated with sub-inhibitory concentrations of EbEO (64, 32, and 16 μg/mL, corresponding, respectively, to 0.125 × MIC, 0.25 × MIC, and 0.5 × MIC). After overnight incubation at 37°C, the tubes were centrifuged (10,000 r/min for 10 min), suspended with 1 mL of phosphate-buffered saline (PBS), and re-centrifuged. Bacteria pellets were then photographed. Following the total carotenoid pigments \[including staphyloxanthin (STX)\] in each pellet were extracted using in methanol (0.2 mL) and incubated for 3 min at 55°C. The methanol phase (supernatant) and cell debris were separated by centrifugation (10,000 r/min for 10 min) and the pellets were submitted to entire pigment extraction procedure three more times. Finally, the absorbance was determined at 465 nm ([@B52]).

Effect of EbEO on Susceptibility of *S. aureus* to Hydrogen Peroxide {#S2.SS8}
--------------------------------------------------------------------

Microbial suspension (standardized at OD~600~ = 1.0; [@B36]) prepared from overnight cultures of *S. aureus* ATCC 29312 were incubated with sub-inhibitory concentrations of EbEO (64, 32, and 16 μg/mL, corresponding, respectively, to 0.125 × MIC, 0.25 × MIC, and 0.5 × MIC). Each culture received H~2~O~2~ to reach a final concentration of 1.5% (v/v) for 60 min and were incubated at 37°C. The percentage of cells surviving the stresses was calculated as CFU/mL remaining after each stress divided by the initial CFU/mL.

Anti-hemolytic Evaluation {#S2.SS9}
-------------------------

*Staphylococcus aureus* ATCC 29312 overnight cultures were diluted at 1:100 in fresh LB and cultured with or without sub-inhibitory concentrations of EbEO (64 and 32 μg/mL) at 37°C. After 16 h (to guarantee a constant number of bacteria present in experiment), 50 μL of culture supernatant was added to 1 mL of 3% human erythrocytes solution. The mixture was incubated at 37°C for 1 h with 250 r/min shaking. The supernatant was collected by centrifugation at 10,000 r/min for 10 min, and the optical density was measured at 540 nm.

Bacterial Activity in Whole Blood {#S2.SS10}
---------------------------------

To verify whether EbEO could enhance the antimicrobial action in whole blood, the *S. aureus* ATCC 29312 (diluted in LB medium; 1:100) was grown in the presence of EbEO (64 and 32 μg/mL) at 37°C with shaking of 250 r/min. After 6 h, the *S. aureus* suspension (62.5 μL) with EbEO (64 or 32 μg/mL) were mixed with freshly drawn human whole blood (0.5 mL) and re-incubated in the conditions described above for 2 h. The samples were plated in LB agar and the survival was measured by counting viable colonies (expressed as CFU/mL) ([@B34]).

Infectious Model With *Caenorhabditis elegans* {#S2.SS11}
----------------------------------------------

The infection model was performance using *C. elegans* AU37, a temperature-sensitive sterile strain \[sek-1(km4); glp-4(bn2) I; MAPK kinase deficiency\] ([@B22]). The strain was propagated on nematode growth medium (NGM) containing *Escherichia coli* OP50 as food source. Prior each assay, the worms were age-synchronized by bleaching with alkaline hypochlorite and sodium hydroxide. The released embryos were placed on NGM plates at 25°C (this temperature does not allow the reproduction) until reached the young adult stage. At this time, 15 larvae were transferred to 24-wells plates containing the M9 liquid medium and overnight culture *S. aureus* ATCC 29312 (grown in LB medium containing 10 μg/mL cholesterol) in a ratio of 4:1 (v/v) ([@B29]). EbEO (128, 64, and 32 μg/mL) was added and the worm longevity was assessed every day. OP 50 was used with positive control (worm and *E. coli*) and *S. aureus* was used with negative control (worm and ATCC 29312). The animals were classified as dead when they did not present spontaneous movement or response after stimulation with a platinum loop. All experiments were performed according to Wormbook ([@B57]).

Infectious Model With *Galleria mellonella* {#S2.SS12}
-------------------------------------------

*Galleria mellonella* larvae (∼200 mg) were randomly distributed in three experimental groups (*n* = 10) with or without oil treatment. Two groups were infected by injection of 10 μL of a recent *S. aureus* ATCC 29312 suspension (1.0 × 10^5^ CFU; different bacterial concentrations was previously optimized to guarantee an inicial sublethal load to this assay), into the last left proleg, followed by incubation at 37°C. After 2 h, one of these groups received 10 μL of 128 μg/mL EbEO (resulting in dose of 6.4 mg/kg). Larvae treated with PBS (vehicle) were used as positive control.

Quantification of *S. aureus* Load in *G. mellonella* Hemolymph {#S2.SS13}
---------------------------------------------------------------

*Galleria mellonella* larvae were infected with *S. aureus* ATCC 29312 and treated with EbEO as described above. Each day, a total of five larvae were cut in the cephalocaudal direction with a scalpel blade and squeezed to remove the hemolymph. Each sample was 10-fold-diluted in PBS and 4 μL was plated on LB agar. After 24h-incubation at 37°C, the colonies were enumerated, and the results expressed as CFU/mL.

Quantification of Hemolymph Melanization {#S2.SS14}
----------------------------------------

Melanization test concerns the production of this pigment under stress conditions. *G. mellonella* (*n* = 10) were infected with *S. aureus* ATCC 29312 (10^6^ cells/larva) aimed to evaluate melanization as a response to higher concentrations of bacteria (stress) and to quantify this response as a function of the melanin/time correlation after being treated with 6.4 mg/kg EbEO. After the incubation (1 or 3 h), the hemolymph was collected and diluted (1:10; v/v) in cold PBS. The cells suspensions were centrifuged at 12,000 r/min and the absorbance of each supernatant was determined at 465 nm.

Statistical Analysis {#S2.SS15}
--------------------

All assays were performed in triplicate in at least two independent experiments. Statistical analyses were performed using the software GraphPad Prism version 7.^[1](#footnote1){ref-type="fn"}^ Data were analyzed by one-way, two-way analysis of variance (ANOVA), and Tukey test. A *p*-value of \< 0.05 was considered as statistically significant. Differences in the survival were determined using the Kaplan--Meier method and log-rank test was used to compare survival curves.

Results {#S3}
=======

EbEO Enhances the Activity of Drugs Toward *S. aureus* {#S3.SS1}
------------------------------------------------------

Initially, we performed a microdilution-based assay to evaluate antimicrobial activity of EbEO against all tested *S. aureus* strains, including those with multidrug resistance profile (MDR strains). This oil inhibited the standard *S. aureus* ATCC 29312 with an MIC of 128 μg/mL, while the MIC values for the other strains ranged from 8 to 516 μg/mL. The MIC~50~ (concentration able to inhibit 50% of the tested strains) was 128 μg/mL ([Table 1](#T1){ref-type="table"}).

Following, a time-kill study was performed using EbEO at 128 μg/mL (2 × MIC) or 1024 μg/mL (8 × MIC). Both oil concentrations were able to inhibit the growth of *S. aureus* ATCC 29312 without any significant differences among them. After 3 h, the oil induced reductions of 50% in the number of viable colonies when compared to untreated cells. The oil exhibited a profile, similar to the observed from ciprofloxacin (0.5 μg/mL) ([Figure 1](#F1){ref-type="fig"}). Further, the action of EbEO was not associated with an increased expression of *recA*, the first gene related with the activation of SOS response, a pathway involved in the DNA repair ([@B64]) ([Figure 2](#F2){ref-type="fig"}).

![Effects of *Eugenia brejoensis* essential oil (EbEO) on growth of *Staphylococcus aureus*. *S. aureus* ATCC 29312 was treated with 2 × MIC (256 μg/mL) or 8 × MIC EbEO (1024 μg/mL). Bacteria treated with ciprofloxacin (CIP at 2 μg/mL; 2 × MIC) or without treatment were used as positive and negative controls, respectively. Samples were taken every hour to assess bacterial viability.](fmicb-11-00424-g001){#F1}

![Effects of *Eugenia brejoensis* essential oil (EbEO) on expression of *recA*. The expression of *recA* was performed using a derivative *S. aureus* 8325-4 strain carrying a *recA:lacZ* fusion. Bacteria were treated with EbEO (64 μg/mL; 0.5 × MIC) or ciprofloxacin (CIP at 0.5 μg/mL; 0.5 × MIC) for 3 h. β-Galactosidase activity was measured using ONPG. \* Indicates significant differences in relation to control cells (*p* \< 0.05).](fmicb-11-00424-g002){#F2}

Next, we determined whether EbEO could improve the action of some antibiotics (from different classes) toward *S. aureus*. EBEO synergistically increased the action of ampicillin (ΣFIC: 0.45), chloramphenicol (ΣFIC: 0.15), and kanamycin (ΣFIC: 0.075), while it had additive effects with ciprofloxacin (ΣFIC: 0.6) and erythromycin (ΣFIC: 0.6).

EbEO Affects the Expression of *Quorum Sensing*-Related Genes of *S. aureus* and Its Hemolytic Activity {#S3.SS2}
-------------------------------------------------------------------------------------------------------

Following, we evaluated the effects of EbEO on the expression of two gene of this system (*hla* and *spa* that encode alpha-hemolysin and protein A, respectively). It is expected that a *quorum sensing* inhibitor (QSI) reduces the expression of *hla* and increases the transcriptional levels of *spa* ([@B44]). Based on this, the results indicated the EbEO (at 0.5 × MIC) could alter the expression of *hla* (downregulation) and *spa* (upregulation), suggesting that this oil is QSI ([Figures 3A,B](#F3){ref-type="fig"}).

![Influence of *Eugenia brejoensis* essential oil (EbEO) on some virulence properties of *S. aureus.* **(A)** Effects of EbEO on expression of *hla* using *S. aureus* 8325-4 derivative strains carrying *hla:lacZ*. **(B)** Effects of EbEO on expression of *spa* using *S. aureus* 8325-4 derivative strains carrying *spa:lacZ*. **(C)** Interference of EbEO on hemolytic activity of *S. aureus*. **(D)** Inhibition of EbEO on *S. aureus* survival on whole blood. \* Indicates significant differences in relation to control cells (*p* \< 0.05).](fmicb-11-00424-g003){#F3}

We further analyzed whether EbEO could decrease the hemolytic activity of *S. aureus* and its ability to survive in human blood. The treatment with EbEO (0.5 × MIC or 0.25 × MIC) strongly inhibited the hemolysis-mediated by *S. aureus* (around 90% of inhibition) ([Figure 3C](#F3){ref-type="fig"}). Similarly, the survival of this pathogen on blood was impaired by subinhibitory concentrations (Sub-MIC) values of EbEO ([Figure 3D](#F3){ref-type="fig"}).

EbEO Inhibits the Production of Staphyloxanthin and Increases the Susceptibility of *S. aureus* to Hydrogen Peroxide {#S3.SS3}
--------------------------------------------------------------------------------------------------------------------

[Figure 4A](#F4){ref-type="fig"} shows that EbEO strongly reduced the levels of staphyloxanthin in a dose-dependent manner (95.63 ± 0.98 and 89.38 ± 1.49% for EbEO at 64 or 32 μg/mL, respectively). In addition, the treatment with EbEO (at 64 or 32 μg/mL; 0.5 × MIC or 0.25 × MIC) potentialized the toxicity of hydrogen peroxide (1.5% v/v) toward *S. aureus* ([Figure 4B](#F4){ref-type="fig"}). Similar levels of viability reduction were observed for both concentrations (24.12 ± 4.19 and 20.87 ± 0.87% for EbEO at 64 and 32 μg/mL, respectively), when compared to cells treated with hydrogen peroxide alone (*p* \< 0.05). These results suggest that the inhibition of staphyloxanthin production by EbEO impaired the antioxidant system of *S. aureus* and increased its susceptibility to oxidant attack. Based on these findings, we decided to evaluate the anti-infective efficacy of EbEO using two alternative experimental models: *C. elegans* and *G. mellonella*.

![*Eugenia brejoensis* essential oil (EbEO) reduces the staphyloxanthin production and *S. aureus* resistance to hydrogen peroxide. **(A)** EbEO inhibits the staphyloxanthin production. **(B)** The survival of *S. aureus* after oxidative stress is reduced by EbEO. \* Indicates significant differences in relation to control cells (*p* \< 0.05). \# Indicates significant differences in relation to H~2~O~2~ cells (*p* \< 0.05).](fmicb-11-00424-g004){#F4}

EbEO Increases the Lifespan of *C. elegans* Infected by *S. aureus* {#S3.SS4}
-------------------------------------------------------------------

The infection of *C. elegans* by *S. aureus* resulted in a reduction of worm viability and 8 days post-infection (dpi) the survival ratio of this group was 30%, while the uninfected animals showed 90% survival at this day ([Figure 5A](#F5){ref-type="fig"}). The median survival of *S. aureus*-infected worms was 7 days. This scenario was radically changed by the treatment with EbEO at 128 or 64 μg/mL. The animals treated with 128 μg/mL EbEO showed survival curve similar to control group (*p* \> 0.05). In the end (8 dpi), the survival of worms treated with EbEO were around 60 and 80%, for concentrations of 64 or 128 μg/mL, respectively ([Figure 5A](#F5){ref-type="fig"}). In addition, the *C. elegans* larvae treated with 128 μg/mL EbEO (MIC) also exhibited lower bacterial load than those incubated with 64 μg/mL EbEO ([Figure 5B](#F5){ref-type="fig"}). It is important to highlight that the tested EbEO concentrations did not significantly reduce the viability of *C. elegans* when compared with PBS-treated group (data not shown).

![*Eugenia brejoensis* essential oil (EbEO) protects *Caenorhabditis elegans* larvae from *Staphylococcus aureus* infection. **(A)** Effects of EbEO on Survival of *C. elegans* larvae infected with *S. aureus*. **(B)** Bacterial load. \* Indicates significant differences in relation to control cells (*p* \< 0.05).](fmicb-11-00424-g005){#F5}

EbEO Protects *Galleria mellonella* Larvae Against the *S. aureus* Infection {#S3.SS5}
----------------------------------------------------------------------------

The antibacterial activity of EbEO was further analyzed using *G. mellonella* larvae. EbEO treatment did not show any toxicity to these larvae, resulting in survival curves similar to those observed to PBS-treated animals (data not shown). The larvae infected with *S. aureus* showed 100% mortality in the third day and this group exhibited a median survival of 1 day. On the other hand, the treatment with a single dose of EbEO (6.4 mg/kg) protected 70% of the larvae at the end of the experiment (4 dpi) ([Figure 6A](#F6){ref-type="fig"}).

![Effects of *Eugenia brejoensis* essential oil (EbEO) on *Galleria mellonella* infected with *S. aureus*. **(A)** EbEO improves the survival of *G. mellonella* infected with *S. aureus*. **(B)** EbEO reduces the load of *S. aureus* in hemolymph. **(C)** Effects of EbEO on melanin production after 1 h of *S. aureus*-infection. **(D)** Effects of EbEO on melanin production after 3 h of *S. aureus*-infection. \* Indicates significant differences in relation to uninfected larvae (*p* \< 0.05). \# Indicates significant differences in relation to uninfected and *S. aureus-*infected larvae (*p* \< 0.05).](fmicb-11-00424-g006){#F6}

Interestingly, EbEO treatment induced small effects on the bacterial load when compared to initial bacterial inoculum (time 0), suggesting a bacteriostatic action ([Figure 6B](#F6){ref-type="fig"}). In relation to *S. aureus-*infected larvae, EbEO-treated animals exhibited significantly lower levels of bacteria in hemolymph in all days evaluated (around 3 log CFU/mL reductions for all days; *p* \< 0.05).

Finally, we evaluated whether EbEO could reduce the overproduction of melanin induced by *S. aureus* infection ([Figures 6C,D](#F6){ref-type="fig"}). We observed that the levels of melanin in the hemolymph of *S. aureus-*infected larvae were significantly increased when compared to PBS-treated group (approximately eightfolds after 1 and 3 h of infection; [Figures 6C,D](#F6){ref-type="fig"}). The treatment with EbEO also significantly reduced the melanin content in hemolymph of *G. mellonella* larvae at both tested period (reductions of 42.19 and 55.41% after 1 and 3 h of infection, respectively; [Figures 6C,D](#F6){ref-type="fig"}).

Discussion {#S4}
==========

Due the high chemical diversity exhibited by EOs, they have been pointed out as interesting source of lead molecules for development of alternative antimicrobial therapies ([@B49]; [@B15]; [@B55]). These studies have encouraged the search of new EOs from unexploited plants, and one current example is *E. brejoensis* a plant recently described in Brazil ([@B38]; [@B17]). Herein, we reported the activity of this oil against *S. aureus*, a pathogen highlighted due its ability to harbor genes related with virulence factors and drug resistance pathways ([@B30]; [@B6]; [@B63]).

EbEO was able to inhibit the *S. aureus* strains with MIC~50~ of 256 μg/mL. As mentioned above, EbEO is mainly composed by sesquiterpenes such as δ-cadinene, β-caryophyllene, α-muurolol, α-cadinol, and bicyclogermacrene ([@B9]). The anti-*S. aureus* activity of EOs containing these sesquiterpenes is well documented in the literature ([@B43]; [@B51]; [@B19]; [@B45]; [@B50]). Our results from time-kill studies demonstrated that EbEO is an antibacterial agent showing a synergetic interaction with ampicillin, chloramphenicol, and kanamycin; and additive effects with ciprofloxacin and erythromycin. The improvement of antibiotic action has been reported for several EOs and isolated sesquiterpenes ([@B32]; [@B31]; [@B15]; [@B25]).

The overuse and misuse of antibiotics has resulted in different gradient of drug concentrations in humans, animals, and environment ([@B2]; [@B21]). In this sense, bacteria are frequently exposed to Sub-MIC of the antimicrobial agent and these conditions could result in mutagenesis and release of microbial virulence factors ([@B2]; [@B23]; [@B33]; [@B21]). Thus, it is important to evaluate the effects of the antimicrobial agents in pathways related to mutagenesis and virulence ([@B20]; [@B13]). We first showed that EbEO did not induce the expression of *recA* which is the first gene in the SOS response. The activation of SOS response occurs when bacteria need to repair damages induced in the DNA due antibiotic treatment and other adverse conditions ([@B53]; [@B52]). The activation of SOS pathway is associated with emergence of drug resistance and acquisition of virulence factors ([@B3]; [@B41]).

Our data also report that EbEO interferes with the regulation of the accessory gene regulator (*agr*)-mediated quorum sensing. This system upregulates the production of secreted virulence factors (such as α-hemolysin encoded by *hla*) and downregulates cell surface proteins (such as protein A encoded by *spa*) ([@B18]; [@B54]). We demonstrated that sub-inhibitory concentrations of EbEO decreased the expression of *hla* and increased the expression of *spa*. Further, *S. aureus* grown in the presence of EbEO displayed reduced hemolytic activity and less ability to survival in whole blood. α-Hemolysin induces toxicity toward a broad range of cells and is associated to severe injuries in cutaneous (skin necrosis) and systemic infections ([@B6]; [@B16]; [@B58]).

Other antivirulence effect of EbEO is the inhibition of STX production, a carotenoid from *S. aureus* membrane that confers protection against reactive oxygen species produced by host defense, allowing the bacteria to persist in the inflammation site ([@B37]; [@B47]). These properties make STX an attractive target for antivirulence therapy as demonstrated for some plant-derived compounds ([@B34]; [@B52]; [@B8]). The inhibitory effects of EbEO toward STX production could be confirmed by the fact that *S. aureus* grown in the presence of this oil showed increased susceptibility to hydrogen peroxide. In addition, it may also relate to the efficacy of EbEO to rescue *C. elegans* and *G. mellonella* from *S. aureus* infection.

*Caenorhabditis elegans* is free-living terrestrial nematode considered a fast, cheap, and efficient model for *in vivo* testing of antimicrobial substances since it is susceptible to human pathogens such as *S. aureus* ([@B29], [@B27]). Our results showed that the treatment with EbEO increased the worm lifespam and decreased the bacterial load. The anti-infective efficacy of EbEO was also demonstrated using *G. mellonella* larvae. EbEO-treated animals also showed lower levels of melanin, a soluble molecule part of the humoral response of *G. mellonella* (together with lysozyme, antimicrobial peptides, and opsonins) ([@B67]; [@B61]). The melanogenesis is part of prophenoloxidase cascade which is activated by pathogens and other foreign particles leading accumulation of nodules in order to control the microbial replication ([@B60]). The melanin overproduction results in high levels of cytotoxic compounds that may induce serious damage to host tissues and cells ([@B66]). In this sense, the oil could also protect the larvae against the deleterious effects related to *S. aureus* infection.

Taken together, the results indicated the EO of *E. brejoensis* is an important source of molecules with anti-*S. aureus* action, even against MDR strains. Importantly, the oil reduced the expression of significant factors involved in *S. aureus* virulence and impaired the ability of this bacterium to survive in adverse conditions such as whole blood and under oxidative stress. The antimicrobial efficacy was confirmed using two alternative models of infections based on *C. elegans* and *G. mellonella*. These data denote the importance of prospecting new species from underexploited environmental (such as Brazilian caatinga) in order to identify new lead molecules for antimicrobial therapy. Further testing is required to know the mode of action of EbEO and details about the action of this oil against the virulence of *S. aureus* as well as individual role of the main components of the EO of *E. brejoensis* are essential for antimicrobial action.
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